MANE

$140.72

+$3.33 (2.42%)Oct 27 close

US Equities Compare Technicals

1M 3M 6M 1Y 2Y

MANESPY

Wall St. Highest PT $192.28 (+36.6%) Wall St. Avg PT $157.61 (+12.0%)

Underwater Drawdown %Max DD -24.8%Current 0.0%

Relative Strength vs SPY+259.7% vs SPYOutperforming

+$13.61 (10.71%)

+$24.15 (20.72%)

+$29.18 (26.16%)

+$37.62 (36.49%)

YTD

–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar

Wall Street & Morningstar coverage

Wall Street consensusNo covering analysts on file for MANE

Analyst price targetsNo target range on file

Morningstar star ratingNot rated

Checked Wall Street & Morningstar feeds · All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

52-week range$37.03 – $140.72

What they do

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy.

Healthcare · Biotechnology

Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for MANE yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth

Outside this model's universe or screens

Momentum Top 15

Outside this model's universe or screens

Momentum Blend

Not in the current book

New Highs Growth

Outside this model's universe or screens

SURVYR. Barbell Momentum & T-Bill Shield

Outside this model's universe or screens

SURVYR. Physical AI Grid & Power

Outside this model's universe or screens

SURVYR. Long Book

Not in the current book

Earnings & events

MANE earningsNext report in 15 days

Next report

Thu Nov 12, 2026Before the open

EPS consensus-$0.62

Revenue consensus–

Last 2 quarters · EPS vs estimate

Aug 11, 2026-$0.58est -$0.64+9.6%Above estimates

Mar 30, 2026-$104.54est -$18.24−473.1%Below estimates

In line = within 1% of the estimate.

EstimateActual (beat)Actual (miss)

News & catalysts

More news

Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study

BioPharma Dive · Oct 19

Insider trades

Montanova Capital, Llc

Director · 2026-08-19

Sell
$6.4M

Montanova Capital, Llc

Director · 2026-08-19

Sell
$74.1M

Waldman Reid Alexander